AU2001258575A1 - Treatment of cancer and neurological diseases - Google Patents

Treatment of cancer and neurological diseases

Info

Publication number
AU2001258575A1
AU2001258575A1 AU2001258575A AU5857501A AU2001258575A1 AU 2001258575 A1 AU2001258575 A1 AU 2001258575A1 AU 2001258575 A AU2001258575 A AU 2001258575A AU 5857501 A AU5857501 A AU 5857501A AU 2001258575 A1 AU2001258575 A1 AU 2001258575A1
Authority
AU
Australia
Prior art keywords
cancer
treatment
neurological diseases
neurological
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258575A
Inventor
Andrew Peter Jackson
Alexander Fred Markham
Christopher Geoffrey Woods
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Publication of AU2001258575A1 publication Critical patent/AU2001258575A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
AU2001258575A 2000-05-20 2001-05-21 Treatment of cancer and neurological diseases Abandoned AU2001258575A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0012186.3A GB0012186D0 (en) 2000-05-20 2000-05-20 Treatment of cancer and neurological diseases
GB0012186 2000-05-20
PCT/GB2001/002240 WO2001090354A1 (en) 2000-05-20 2001-05-21 Treatment of cancer and neurological diseases

Publications (1)

Publication Number Publication Date
AU2001258575A1 true AU2001258575A1 (en) 2001-12-03

Family

ID=9891971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258575A Abandoned AU2001258575A1 (en) 2000-05-20 2001-05-21 Treatment of cancer and neurological diseases

Country Status (5)

Country Link
US (1) US20030180750A1 (en)
EP (1) EP1283883A1 (en)
AU (1) AU2001258575A1 (en)
GB (1) GB0012186D0 (en)
WO (1) WO2001090354A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820861A3 (en) * 2000-08-02 2007-08-29 Amgen Inc. C3B/C4B complement receptor-like molecules and uses thereof
AU2001280733B2 (en) * 2000-08-02 2007-04-26 Amgen Inc. C3B/C4B complement receptor-like molecules and uses thereof
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
EP1341812A2 (en) * 2000-11-08 2003-09-10 Incyte Genomics, Inc. Secreted proteins
WO2002064791A2 (en) * 2000-12-08 2002-08-22 Curagen Corporation Proteins and nucleic acids encoding same
US6975943B2 (en) 2001-09-24 2005-12-13 Seqwright, Inc. Clone-array pooled shotgun strategy for nucleic acid sequencing

Also Published As

Publication number Publication date
US20030180750A1 (en) 2003-09-25
GB0012186D0 (en) 2000-07-12
WO2001090354A1 (en) 2001-11-29
EP1283883A1 (en) 2003-02-19

Similar Documents

Publication Publication Date Title
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002324914A1 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
AU2001279707A1 (en) Diagnosis of behavioural disorders, neurological disorders and cancer
AU7434101A (en) Treatment of bone diseases
AU7863201A (en) Treatment of hyperproliferative diseases
AUPQ923100A0 (en) Treatment of prostate cancer
AUPQ877300A0 (en) Topical treatment of skin
AU2000258352A1 (en) Acupuncture points stimulation for treating various diseases
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AUPQ201499A0 (en) Treatment of inflammatory and malignant diseases
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
AU3896900A (en) Treatment of pain
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
AU2001258575A1 (en) Treatment of cancer and neurological diseases
AU7106300A (en) Treatment of skin disorders
AU2002229986A1 (en) Method of treating neurological diseases
AU7636800A (en) Improved ricin-like toxins for treatment of cancer
AU4215499A (en) Treatment of neurodegenerative diseases
AU2001245414A1 (en) Treatment of allergies
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU1405001A (en) Treatment of diseases